[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics[J].CA Cancer J Clin,2018, 68:7-30.
|
[2] |
Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia,Canada, Denmark, Norway, Sweden, and the UK,1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data[J]. Lancet, 2011,377:127-138.
|
[3] |
Teliga-Czajkowska J, Sienko J, Jalinik K,et al. Plasminogen activator inhibitor type1 in blood at onset of chemotherapy unfavorably affects survival in primary ovarian cancer[J]. Adv Exp Med Biol,2019,5: 47-54.
|
[4] |
Yang J, Jin Y, Cheng S,et al.Clinical signifcance for combined coagulation indexes in epithelial ovarian cancer prognosis[J]. J Ovarian Res,2021,14:106-116.
|
[5] |
Cho MS,Li J,Gonzalez-Delgado R,et al. The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer[J]. Blood Adv, 2021, 5:1947-1951.
|
[6] |
Falanga A, Marchetti M, Russo L.The mechanisms of cancer-associated thrombosis[J]. Thromb Res, 2015,135:S8-S11.
|
[7] |
Jaiswal RK, Varshney AK, Yadava PK. Diversity and functional evolution of the plasminogen activator system[J]. Biomed Pharmacother,2018,98:886-898.
|
[8] |
Haemmerle M,Taylor ML,Gutschner T,et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling[J]. Nat Commun,2017,8:310.doi:10.1038/s41467-017-00411-z.
|
[9] |
Li W, Tang Y, Song Y, et al. Prognostic role of pretreatment plasma D-Dimer in patients with solid tumors: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 45: 1663-1676.
|
[10] |
Lal I, Dittus K,Holmes CE.Platelets, coagulation and fibrinolysis in breast cancer progression[J].Breast Cancer Res,2013, 15:207-219.
|
[11] |
吴梦,娄鉴芳,黄珮珺,等. 卵巢癌细胞通过p38 MAPK通路促进CD8+调节T细胞的生成[J]. 基础医学与临床, 2016, 36: 167-172.
|
[12] |
Bortot B, Mangogna A, Peacock B,et al.Platelet activation in ovarian cancer ascites: assessment of GPIIb/IIIa and PF4 in small extracellular vesicles by nano-flow cytometry analysis[J]. Cancers, 2022, 14:4100 doi:10.3390/cancers14174100.
|
[13] |
李少儒,秦海霞,刘珊珊,等.miR-493-5p抑制人卵巢癌细胞系SKOV3增殖和迁移[J].基础医学与临床,2021,41:1749-1755.
|
[14] |
Collinson FJ, Seligmann J, Perren TJ.Ovarian cancer: advances in first-line treatment strategies with a particular focus on antiangiogenic agents[J].Current oncol Rep,2012,14:509-518.
|
[15] |
Rubio-Jurado B, Balderas-Penal M, Garcia-Lunae E, et al. Obesity, thrombotic risk, and inflammation in cancer[J]. Adv Clin Chem, 2018, 85: 71-89.
|
[16] |
Reiser E,Pils D,Grimm C,et al.Defining models to classify between benign and malignant adnexal masses using routine laboratoryparameters[J].Cancers, 2022,14:3210. doi:10.3390/cancers14133210.
|